Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)
Số trang: 6
Loại file: pdf
Dung lượng: 1.04 MB
Lượt xem: 7
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Dacomitinib is a second-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). ARCHER-1050 showed that this agent can improve progression-free survival and overall survival in advanced non-small cell lung cancer patients with sensitive EGFR mutation compared to gefitinib.
Nội dung trích xuất từ tài liệu:
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)
Nội dung trích xuất từ tài liệu:
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Non-small cell lung cancer Irreversible epidermal growth factor receptor Tyrosine kinase inhibitor EGFR mutationGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 167 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 109 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 35 0 0
-
12 trang 33 0 0